Company intelligence / Profile preview
Diartis Pharmaceuticals
Redwood City, California, United Statesdiartispharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 1 trial of VRS-859 (exenatide-XTEN), a long-acting GLP-1 analog, showing safety, tolerability, dose-proportional PK, significant HbA1c reductions, and body weight decreases in T2DM patients after single doses up to 200 mg. Planned 6-month repeat-dose study.
- Therapeutic areas
- Endocrinology
- Modalities
- Fusion protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Index VenturesAmunix
Beyond the preview
Go deeper on Diartis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diartis Pharmaceuticals.